Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Quince Therapeutics

Request full access

Cortexyme is developing novel treatments for altering the course of Alzheimer's and other neurological diseases

South San Francisco, United StatesFounded 2012Biotech & Life Sciences

About Quince Therapeutics

Quince Therapeutics, Inc. operates as a late-stage biopharmaceutical company, strategically focused on developing and commercializing therapeutics for rare and debilitating diseases. Initially incorporated as Cortexyme, Inc. in 2012 by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric, the company rebranded to Quince Therapeutics in August 2022.

A pivotal moment in the company's recent history was the acquisition of EryDel S.p.A., a privately-held Italian biotech firm, in October 2023. This transaction was structured as a stock-for-stock exchange with no upfront cash, but includes potential downstream milestone payments of up to $485 million. Through this acquisition, Quince obtained EryDel's lead asset, now named eDSP (formerly EryDex), and its proprietary drug delivery technology. The company's business model is centered on advancing its clinical pipeline, funded by cash reserves and strategic partnerships, rather than revenue from product sales. As a clinical-stage entity, its financial health is characterized by significant investment in research and development.

The company is led by CEO and CMO Dr. Dirk Thye, a seasoned executive with extensive experience in biotechnology, company creation, and drug development, having led multiple companies to successful exits and FDA approvals. His background spans infectious diseases, oncology, inflammation, and CRISPR gene editing. Dr. Thye previously served as CEO of Novosteo, which Quince acquired in May 2022.

Quince's core technology is the Autologous Intracellular Drug Encapsulation (AIDE) platform, a drug/device combination that encapsulates pharmaceuticals within a patient's own red blood cells. This method is designed to optimize drug delivery by improving tolerability, enhancing biodistribution, prolonging circulating half-life, and reducing immunogenicity. The primary application of the AIDE platform is eDSP, which encapsulates dexamethasone sodium phosphate (DSP). This formulation aims to deliver the anti-inflammatory benefits of corticosteroids for treating Ataxia-Telangiectasia (A-T), a rare pediatric neurodegenerative disease, while minimizing the severe side effects associated with long-term steroid use. There are currently no approved treatments for A-T. The company completed enrollment for its pivotal Phase 3 NEAT clinical trial for eDSP in July 2025 and anticipates reporting topline results in the first quarter of 2026.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2019

Quince Therapeutics in the South San Francisco ecosystem

Live from Dealroom

The Quince Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

23 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Pfizer Ventures

Series A21 investors entered at this stage

Series B and later1 investor entered at this stage

  • Breakout Ventures
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States77.8%
🇮🇹 Italy16.7%
🇬🇧 United Kingdom5.6%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Quince Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Quince Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.